IL6 and cancer: It also decreased the activation of transcriptional regulators that promote metastasis or inflammation.319 This combined therapy also enhanced the production of IL-12, IFN-γ and CD11a, inhibited the secretion of IL-6 and C-reactive protein, and reduced the mobilization of CD16− monocytes.319 These findings suggest that targeting the adrenergic signaling pathway may be a promising strategy to improve the effectiveness of cancer immunotherapies and that the timing and combination of such interventions could be critical in optimizing treatment outcomes.